Comparison of immunogenicity between hepatitis B vaccines with different dosages and schedules among healthy young adults in China: A 2-year follow-up study

References

• WHO. Global Hepatitis Report, 2017. Geneva: WHO, 2017. http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/
   Google Scholar
• Zhou YH, Wu C, Zhuang H. Vaccination against hepatitis B: The Chinese experience. Chin Med J (Engl). 2009;122:98–102. PMID:19187625.
   PubMed Web of Science ®Google Scholar
• Cui F, Shen L, Li L, Wang H, Wang F, Bi S, Liu J, Zhang G, Wang F, Zheng H, et al. Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China. Emerg Infect Dis. 2017;23:765–72. PMID:28418296. https://doi.org/10.3201/eid2305.161477.
   PubMed Web of Science ®Google Scholar
• WHO. Hepatitis B vaccines: WHO position paper. Wkly Epidemiol Rec. 2009;84:405–19. PMID:19817017.
   PubMedGoogle Scholar
• Zamani F, Fallahian F, Hashemi F, Shamsaei Z, Alavian SM. Immune response to hepatitis B vaccine in health-care workers. Saudi J Kidney Dis Transpl. 2011;22:179–84. PMID:21196642.
   PubMedGoogle Scholar
• Lin SY, Liu JH, Wang SM, Wang IK, Tsai CA, Liu YL, Lin HH, Chang CC, Huang CC. Association of response to hepatitis B vaccination and survival in dialysis patients. Bmc Nephrol. 2012;13:97. PMID:22935561. https://doi.org/10.1186/1471-2369-13-97.
   PubMed Web of Science ®Google Scholar
• Psevdos G, Kim JH, Groce V, Sharp V. Efficacy of double-dose hepatitis B rescue vaccination in HIV-infected patients. AIDS Patient Care STDS. 2010;24:403–7. PMID:20586648. https://doi.org/10.1089/apc.2009.0340.
   PubMed Web of Science ®Google Scholar
• Wang ZZ, Li MQ, Wang P, Yang ZX, Wei L, Zeng Y, Li YP, Yan L, Liu XE, Zhuang H. Comparative immunogenicity of hepatitis B vaccine with different dosages and schedules in healthy young adults in China. Vaccine. 2016;34:1034–9. PMID:26801063. https://doi.org/10.1016/j.vaccine.2016.01.018.
   PubMed Web of Science ®Google Scholar
• China foundation for hepatitis prevention and control (CFFH). An investigation report on the current status of prevention and control of hepatitis B among college students in China. Beijing: CFFH; 2009.
   Google Scholar
• Potsch DV, Camacho LA, Tuboi S, Villar LM, Miguel JC, Ginuino C, Silva EF, Mendonca RM, Moreira RB, Barroso PF. Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults. Vaccine. 2012;30:5973–7. PMID:22828589. https://doi.org/10.1016/j.vaccine.2012.07.028.
   PubMed Web of Science ®Google Scholar
• Lin SY, Liu JH, Wang SM, Wang IK, Tsai CA, Liu YL, Lin HH, Chang CC, Huang CC. Association of response to hepatitis B vaccination and survival in dialysis patients. Bmc Nephrol. 2012;13:97. PMID:22935561; https://doi.org/10.1186/1471-2369-13-97.
   PubMed Web of Science ®Google Scholar
• Tielemans CL, Vlasak J, Kosa D, Billiouw JM, Verpooten GA, Mezei I, Ryba M, Peeters PC, Mat O, Jadoul MY, et al. Immunogenicity and safety of an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination: Results of two open, randomized, comparative trials. Vaccine. 2011;29:1159–66. PMID:21167859. https://doi.org/10.1016/j.vaccine.2010.12.009.
   PubMed Web of Science ®Google Scholar
• Pan HX, Zeng Y, Song XF, Zhang YJ, Xu K, Liang ZL, Zhu FC. Immune response to hepatitis B vaccine with high antigen content in non-responders after standard primary vaccination in Chinese adults. Vaccine. 2014;32:3706–12. PMID:24681228. https://doi.org/10.1016/j.vaccine.2014.02.094.
   PubMed Web of Science ®Google Scholar
• Ma FB, Tang WJ, Lu PS, Hu Y, Kang GD, Yang MW. Study on the Immunogenicity of one dose of 60 μg/1.0ml Recombinant Yeast Derived Hepatitis B Vaccine (Saccharomyces Cerevisiae) Among Health Population Older than 16 Years. Shiyong Yufang Yixue (Chinese). 2013;20(6):653–5.
   Google Scholar
• Stroffolini T, Guadagnino V, Caroleo B, De Sarro G, Foca A, Liberto MC, Giancotti A, Barreca GS, Marascio N, Lombardo FL, et al. Long-term immunogenicity of hepatitis B vaccination in children and adolescents in a southern Italian town. Infection. 2012;40:299–302. PMID:22173948. https://doi.org/10.1007/s15010-011-0233-2.
   PubMed Web of Science ®Google Scholar
• Zanetti AR, Mariano A, Romano L, D'Amelio R, Chironna M, Coppola RC, Cuccia M, Mangione R, Marrone F, Negrone FS, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet. 2005;366:1379–84. PMID:16226616. https://doi.org/10.1016/S0140-6736(05)67568-X.
   PubMed Web of Science ®Google Scholar
• Scheiermann N, Gesemann M, Maurer C, Just M, Berger R. Persistence of antibodies after immunization with a recombinant yeast-derived hepatitis B vaccine following two different schedules. Vaccine. 1990;8 Suppl:S44-6, S60–2. PMID:2139282.
   PubMedGoogle Scholar
• Jilg W, Schmidt M, Deinhardt F, Zachoval R. Hepatitis B vaccination: How long does protection last? Lancet. 1984;2:458. PMID:6147519.
   PubMed Web of Science ®Google Scholar
• Jilg W, Schmidt M, Deinhardt F. Decline of anti-HBs after hepatitis B vaccination and timing of revaccination. Lancet. 1990;335:173–4. PMID:1967468.
   PubMed Web of Science ®Google Scholar
• Lu CY, Ni YH, Chiang BL, Chen PJ, Chang MH, Chang LY, Su IJ, Kuo HS, Huang LM, Chen DS, et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15–18 years after neonatal immunization. J Infect Dis. 2008;197:1419–26. PMID:18444799. https://doi.org/10.1086/587695.
   PubMed Web of Science ®Google Scholar
• Leuridan E, Van Damme P. Hepatitis B and the need for a booster dose. Clin Infect Dis. 2011;53:68–75. PMID:21653306; https://doi.org/10.1093/cid/cir270.
   PubMed Web of Science ®Google Scholar
• Wang ZZ, Gao YH, Lu W, Jin CD, Zeng Y, Yan L, Ding F, Li T, Liu XE, Zhuang H. Long-term persistence in protection and response to a hepatitis B vaccine booster among adolescents immunized in infancy in the western region of China. Hum Vaccin Immunother. 2017;13:909–15. PMID:27874311. https://doi.org/10.1080/21645515.2016.1250990.
   PubMed Web of Science ®Google Scholar
• Schonberger K, Riedel C, Ruckinger S, Mansmann U, Jilg W, Kries RV. Determinants of long-term protection after hepatitis B vaccination in infancy: a meta-analysis. Pediatr Infect Dis J. 2013;32:307–13. PMID:23249904. https://doi.org/10.1097/INF.0b013e31827bd1b0.
   PubMed Web of Science ®Google Scholar
• Velu V, Nandakumar S, Shanmugam S, Shankar EM, Thangavel S, Kulkarni PS, Thyagarajan SP. Comparative efficacy of two dosages of recombinant hepatitis B vaccine in healthy adolescents in India. Pediatr Infect Dis J. 2007;26:1038–41. PMID:17984812. https://doi.org/10.1097/INF.0b013e3181342887.
   PubMed Web of Science ®Google Scholar
• Levie K, Gjorup I, Skinhoj P, Stoffel M. A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults. Scand J Infect Dis. 2002;34:610–4. PMID:12238579. https://doi.org/10.1080/00365540110080881.
   PubMed Web of Science ®Google Scholar
• Wang H, Cai B, Rao D, Liu M, Li Y, Liang X, Cui F, Zhang G, Wang F, Pang X, et al. Rapid immunization effects of a new type of 60 mug hepatitis B vaccine compared with traditional 20 mug hepatitis B vaccines in adults. Hum Vaccin Immunother. 2016;12:2921–6. PMID:27648684. https://doi.org/10.1080/21645515.2016.1206676.
   PubMed Web of Science ®Google Scholar